Review

Maturity-Onset Diabetes of the Young: Mutations, Physiological Consequences, and Treatment Options

Hazar Younis 1,†, Se Eun Ha 1,†, Brian G. Jorgensen 1, Arushi Verma 2 and Seungil Ro 1,3,*

1 Department of Physiology and Cell Biology, University of Nevada School of Medicine, Reno, NV 89557, USA
2 Department of Pediatrics, Division of Pediatric Endocrinology, University of Nevada School of Medicine, Reno, NV 89557, USA
3 RosVivo Therapeutics, Applied Research Facility, Reno, NV 89557, USA
* Correspondence: sro@med.unr.edu
† These authors contributed equally to this work.

Abstract: Maturity-Onset Diabetes of the Young (MODY) is a rare form of diabetes which affects between 1% and 5% of diagnosed diabetes cases. Clinical characterizations of MODY include onset of diabetes at an early age (before the age of 30), autosomal dominant inheritance pattern, impaired glucose-induced secretion of insulin, and hyperglycemia. Presently, 14 MODY subtypes have been identified. Within these subtypes are several mutations which contribute to the different MODY phenotypes. Despite the identification of these 14 subtypes, MODY is often misdiagnosed as type 1 or type 2 diabetes mellitus due to an overlap in clinical features, high cost and limited availability of genetic testing, and unfamiliarity with MODY outside of the medical profession. The primary aim of this review is to investigate the genetic characterization of the MODY subtypes. Additionally, this review will elucidate the link between the genetics, function, and clinical manifestations of MODY in each of the 14 subtypes. In providing this knowledge, we hope to assist in the accurate diagnosis of MODY patients and, subsequently, in ensuring they receive appropriate treatment.

Keywords: maturity-onset diabetes of the young (MODY); diabetes

1. Introduction

Maturity-Onset Diabetes of the Young (MODY) is a monogenic type of diabetes. It is characterized by early onset of diabetes (before the age of 30), dominant autosomal inheritance, and hyperglycemia [1–3]. The mutated MODY genes often result from a single nucleotide substitution [4,5]. The involved genes are essential for proper pancreatic beta cell development and function. However, in mutated genes, glucose sensing and insulin secretion is impaired [1,3,6,7]. Mutations in hepatocyte nuclear factor 1–α (HNF1A), hepatocyte nuclear factor 1–β (HNF1B), hepatocyte nuclear factor 4–α (HNF4A), and glucokinase (GCK) account for most diagnosed MODY cases [2]. Furthermore, many of these genes are discovered to work in hierarchical fashion, assisting or hindering in the activation of other genes [8,9]. Even in the same MODY subtype, mutations can differ in terms of prevalence, clinical manifestations, and disease severity [7,10–12].

MODY is often misdiagnosed as type 1 (T1DM) or type 2 diabetes mellitus (T2DM) [2,13,14]. This can be avoided with adequate clinical knowledge and proper diagnostic techniques [15–18]. A simple key to distinguishing between T1DM or T2DM and MODY is age of diagnosis and parental history of diabetes [3,5,19–21]. One element complicating accurate diagnosis is low penetrance with certain subtypes of MODY, such as those with mutations in NEUROD1 [10,22]. A solid foundation in MODY subtypes and their genetic descriptions is critical for proper diagnosis and treatment of afflicted individuals.
2. Genetic Mutations and Functional Phenotypes in MODY Subtypes

The genetic mutations, diabetic phenotypes, and treatments related to MODY1–14 subtypes are summarized in Tables 1 and 2. The genetic mutations are well linked to hyperglycemia in all the subtypes. In addition, most mutations in the subtypes are also associated with hypoinsulinemia (Table 2). As previously published by Fajans and Brown, sulfonylurea-based drugs substantially augment the glucose-induced increases in plasma levels of insulin [24]. In addition, only MODY 3–5 have been reported to be treated with meglitinides [25], glucagon-like peptide-1 receptor agonists [26], sodium-glucose co-transporter-2 inhibitors [27], metformin [28], dipeptidyl peptidase-4 inhibitors [29], or repaglinide [30] in case reports (Table 2).

Table 1. Genetic mutations and clinical significance in MODY subtypes.

| Subtype          | Gene Name               | Gene Symbol | Locus      | Mutation  | Amino Acid                  | Clinical Significance             | Ref.       |
|------------------|-------------------------|-------------|------------|-----------|----------------------------|----------------------------------|-----------|
| MODY 1           | Hepatocyte nuclear factor 4a | HNF4A       | 20q13.12   | 763C>T    | Gln255Ter                   | Mild hyperglycemia               | [3,31]    |
|                  |                         |             |            | 826G>C    | Glu276Gln                   |                                   |           |
| MODY 2           | Glucokinase             | GCK         | 7p13       | 897G>C    | Leu30Pro                    | Mild hyperglycemia               | [5,32–36] |
|                  |                         |             |            | 203G>T    | Gly68Val                    |                                   |           |
|                  |                         |             |            | 748C>T    | Arg250Cys                   |                                   |           |
|                  |                         |             |            | 905T>A    | Val302Glu                   |                                   |           |
|                  |                         |             |            | 1363G>C   | Ala455Leu                   |                                   |           |
| MODY 3           | Hepatocyte nuclear factor 1a | HNF1A      | 12q24.31   | 511C>G    | Arg171Gly                   | Neonatal hypoglycemia            | [19,20,37,38] |
|                  |                         |             |            | 733G>C    | Gly245Arg                   |                                   |           |
|                  |                         |             |            | 788G>A    | Arg263His                   |                                   |           |
|                  |                         |             |            | 1460G>A   | Ser487Asn                   |                                   |           |
| MODY 4           | Insulin promoter factor 1 | PDX1       | 13q12.2    | 176A>T    | Gln59Leu                    | Neonatal hypoglycemia            | [10,21,39–41] |
|                  |                         |             |            | 188del    | Pro63fs                      |                                   |           |
|                  |                         |             |            | 533A>G    | Glu178Gly                   |                                   |           |
|                  |                         |             |            | 590G>A    | Arg197His                   |                                   |           |
|                  |                         |             |            | 947G>A    | Gly316Asp                   |                                   |           |
| MODY 5           | Hepatocyte nuclear factor 1b | HNF1B      | 17q12      | 335G>C    | Arg112Pro                   | Renal disease                    | [22,42–48] |
|                  |                         |             |            | 406C>G    | Gln136Glu                   | Diabetic ketoaciduria            |           |
|                  |                         |             |            | 490A>C    | Lys164Gln                   | Glomerulocystic kidney disease   |           |
|                  |                         |             |            | 494G>A    | Arg165His                   |                                   |           |
|                  |                         |             |            | 884G>A    | Arg295His                   |                                   |           |
| MODY 6           | Neuronal differentiation 1 | NEUROD1    | 2q31.3     | 34G>C    | Gly12Arg                    | Adult onset (mid-20s)            | [49,50]   |
|                  |                         |             |            | 590C>A    | Pro197His                   |                                   |           |
| MODY 7           | KLF transcription factor 11 | KLF11      | 2p25.1     | 86G>A    | Arg29Gln                    | Pancreatic malignancy            | [51–54]   |
|                  |                         |             |            | 185A>G    | Gln62Arg                    |                                   |           |
|                  |                         |             |            | 659C>T    | Thr220Met                   |                                   |           |
|                  |                         |             |            | 1039G>T   | Ala347Ser                   |                                   |           |
| MODY 8           | Carboxyl ester lipase    | CEL         | 9q34.13    | 1402G>A   | Ala468Thr                   | Adult onset (36 years)           | [18,55,56] |
|                  |                         |             |            | 1454T>C   | Ile485Thr                   | Hypoglycemia                     |           |
| MODY 9           | Paired box 4            | PAX4        | 7q32.1     | 385C>T    | Arg129Thr                   | Nephrological diseases           | [57,58]   |
|                  |                         |             |            | 514C>T    | Arg172Trp                   |                                   |           |
|                  |                         |             |            | 539G>A    | Ser180Asn                   |                                   |           |
| MODY 10          | Insulin                 | INS         | 11p15.5    | 25C>T    | Pro95Ser                    | Neonatal hypoglycemia            | [59–61]   |
|                  |                         |             |            | 130G>A    | Gly44Arg                    |                                   |           |
|                  |                         |             |            | 137G>A    | Arg46Gln                    |                                   |           |
|                  |                         |             |            | 155C>A    | Pro52His                    |                                   |           |
|                  |                         |             |            | 290C>G    | Thr97Ser                    |                                   |           |
Table 1. Cont.

| Subtype    | Gene Name                                      | Gene Symbol | Locus  | Mutation DNA | Amino Acid | Clinical Significance              | Ref.     |
|------------|-----------------------------------------------|-------------|--------|--------------|------------|------------------------------------|---------|
| MODY 11    | BLK proto-oncogene, Src family tyrosine kinase| BLK         | 8p23.1 | 41C>T        | Pro14Leu   | Neonatal hypoglycemia, obesity     | [62–64] |
|            |                                               |             |        | 116C>T       | Pro39Leu   |                                     |         |
|            |                                               |             |        | 164A>G       | His55Arg   |                                     |         |
|            |                                               |             |        | 177C>G       | Asp59Glu   |                                     |         |
|            |                                               |             |        | 187G>A       | Val63Met   |                                     |         |
|            |                                               |             |        | 311G>T       | Arg104Ile  |                                     |         |
|            |                                               |             |        | 391C>T       | Arg131Trp  |                                     |         |
|            |                                               |             |        | 713G>A       | Arg238Gln  |                                     |         |
|            |                                               |             |        | 311G>T       | Pro14Leu   |                                     |         |
|            |                                               |             |        | 311G>T       | Pro39Leu   |                                     |         |
|            |                                               |             |        | 311G>T       | His55Arg   |                                     |         |
|            |                                               |             |        | 311G>T       | Asp59Glu   |                                     |         |
|            |                                               |             |        | 311G>T       | Val63Met   |                                     |         |
|            |                                               |             |        | 311G>T       | Arg104Ile  |                                     |         |
|            |                                               |             |        | 311G>T       | Arg131Trp  |                                     |         |
|            |                                               |             |        | 311G>T       | Arg238Gln  |                                     |         |
|            |                                               |             |        | 311G>T       | Pro14Leu   |                                     |         |
|            |                                               |             |        | 311G>T       | Pro39Leu   |                                     |         |
|            |                                               |             |        | 311G>T       | His55Arg   |                                     |         |
|            |                                               |             |        | 311G>T       | Asp59Glu   |                                     |         |
|            |                                               |             |        | 311G>T       | Val63Met   |                                     |         |
|            |                                               |             |        | 311G>T       | Arg104Ile  |                                     |         |
|            |                                               |             |        | 311G>T       | Arg131Trp  |                                     |         |
|            |                                               |             |        | 311G>T       | Arg238Gln  |                                     |         |
| MODY 12    | ATP binding cassette subfamily C member       | ABCC8       | 11p15.1| 502C>T       | Arg168Cys  | Renal diabetes                     | [65–68] |
|            |                                               |             |        | 2477G>A      | Gly826Asp  |                                     |         |
|            |                                               |             |        | 3158G>A      | Ser1053Asn |                                     |         |
|            |                                               |             |        | 3202T>A      | Phe1068Ile |                                     |         |
|            |                                               |             |        | 4148C>G      | Gly1383Ala |                                     |         |
|            |                                               |             |        | 4500C4A      | Ser1500Arg |                                     |         |
| MODY 13    | Potassium inwardly rectifying channel subfamily J member 11 | KCNJ11 | 11p15.1| 67A>G        | Lys23Glu   | Renal diabetes, Hyperinsulinemic hypoglycemia | [69–73] |
|            |                                               |             |        | 679G>A       | Glu227Lys  |                                     |         |
|            |                                               |             |        | 808C>G       | Leu270Val  |                                     |         |
|            |                                               |             |        | 902G>A       | Arg301His  |                                     |         |
|            |                                               |             |        | 964G>A       | Glu322Lys  |                                     |         |
|            |                                               |             |        | 973C>A       | Arg325Ser  |                                     |         |
|            |                                               |             |        | 1034C>T      | Thr345Met  |                                     |         |
|            |                                               |             |        | 1040G>A      | Arg347His  |                                     |         |
| MODY 14    | Leucine zipper containing 1                   | APPL1       | 3p14.3 | 280G>A       | Asp94Asn   | Wolfram or DIDMOAD syndrome         | [74–77] |
|            |                                               |             |        | 1655T>A      | Leu552Thr  |                                     |         |
|            |                                               |             |        | 1926A>G      | Ile642Met  |                                     |         |

*Fs, frameshift.

Table 2. Pathologies, phenotypes, and treatments of MODY subtypes.

| Subtype    | Pathophysiology                                      | Phenotype     | Treatment                                      | Ref.     |
|------------|------------------------------------------------------|---------------|-----------------------------------------------|---------|
| MODY 1     | Progressive decrease in insulin secretion β-cell dysfunction | ↑             | Sulfonylureas, insulin                        | [78]    |
|            | Worsening of glucose control                         | ↓             |                                               |         |
|            | Low levels of apolipoproteins and triglycerides      |               |                                               |         |
|            | Neonatal hypoglycemia                                |               |                                               |         |
| MODY 2     | Higher glucose threshold for insulin release β-cell dysfunction | ↑             | Treatment is unnecessary                      | [78–82]|
|            | Glucose-sensing defects                              | ↓             |                                               |         |
|            | Mild hyperglycemia (HbA1c 7.3–7.5%)                  |               |                                               |         |
| MODY 3     | Insufficient glucose-mediated insulin secretion β-cell dysfunction | ↑             | Sulphonylureas (additional meglitinides, GLP-1 RA, SGLT-2 inhibitors), insulin | [25,82–88]|
|            | Low glucose renal threshold                          | ↓             |                                               |         |
| MODY 4     | β-cell dysfunction                                   | ↑             | Sulphonylureas, insulin, metformin, dipeptidyl peptidase-4 inhibitors | [29,78,89]|
|            | Impaired glucose-mediated insulin secretion          | NA            |                                               |         |
|            | Mild form of diabetes                                |               |                                               |         |
|            | Overweight/obesity in some patients                  |               |                                               |         |
| MODY 5     | β-cell dysfunction                                   | ↑             | Sulfonylurea, repaglinide, GLP-1 RA, insulin   | [45,46,78,90–93]|
|            | Decreased insulin secretion with progressive worsening of glucose control | ↑             | Genetic/malian malformations                  |         |
|            | Genitourinary malformations                          | NA            |                                               |         |
| MODY 6     | β-cell dysfunction                                   | ↑             | Insulin                                        | [94–96] |
|            | Insulinopenia or insulin resistance                  | NA            |                                               |         |
|            | Different degrees of hyperglycemia                   |               |                                               |         |
| MODY 7     | Decreased glucose sensitivity of β-cells              | ↑             | Insulin                                        | [51,53,97–99]|
|            | Decreased sensitivity to insulin                     | ↓             |                                               |         |
|            | Mild hyperglycemia                                  |               |                                               |         |
Table 2. Cont.

| Subtype   | Pathophysiology                                                                 | Phenotype | Treatment | Ref.                      |
|-----------|--------------------------------------------------------------------------------|-----------|-----------|---------------------------|
| MODY 8    | Impaired endocrine Exocrine pancreatic insufficiency (dysfunction of the mature acinar cell) | ↑         | ↓         | OHAs or insulin [78,100–103] |
| MODY 9    | β-cell dysfunction Progressive hyperglycemia Occurrences of ketoacidosis     | ↑         | NA        | OHAs or insulin [96,97,104,105] |
| MODY 10   | Hyperglycemia β-cell dysfunction   | ↑         | ↓         | Insulin [61,106–109]    |
| MODY 11   | Hyperglycemia β-cell dysfunction   | ↑         | NA        | OHAs or insulin [62,110–113] |
| MODY 12   | Impaired insulin secretion ATP-sensitive potassium channel dysfunction | ↑         | ↓         | Insulin, sulfonylureas [67,78,114–120] |
| MODY 13   | Impaired insulin secretion ATP-sensitive potassium channel dysfunction | ↑         | NA        | Sulfonylureas [121–129]   |
| MODY 14   | Impaired glucose-mediated insulin secretion Hyperglycemia Reduced beta cell survival | ↑         | ↓         | OHAs or insulin [74–77,130] |

↑, hyperglycemia or hyperinsulinemia; ↓, hypoinsulinemia; N/A, not available; OHAs, oral anti-hypoglycemic agents; GLP-1 RA, glucagon-like peptide-1 receptor agonist; SGLT-2, sodium-glucose cotransporter-2.

2.1. HNF4A-MODY1 (MODY1)

MODY1 corresponds with the HNF4A gene on chromosome 20. HNF4A encodes a transcription factor that belongs to the steroid/thyroid hormone receptor family. HNF4A is expressed primarily in the kidney, liver, gut, and pancreatic islets [4,6,131,132]. It plays a role in the metabolism of cholesterol, fatty acids, amino acids, and glucose. A previous study has reported that HNF4A regulates genes involved in glucose transport, glucose homeostasis, and genes essential to the functioning of pancreatic islet [6]. Yamagata et al. reported that mutations in HNF4A can cause a form of non-insulin-dependent (type 2) diabetes mellitus (maturity-onset diabetes of the young; gene named MODY1) [31]. MODY1 patients suffer from impairments in β-cell function with normal insulin sensitivity. Besides their β-cell associated phenotypes, MODY1 patients show impairments in glucagon and pancreatic polypeptide secretion, and decreased triglyceride and apolipoprotein biosynthesis [132,133].

There are several mutations that occur in the gene (Table 1), most of which are in the DNA binding, dimerization, and putative ligand domain. The first MODY1 mutation to be identified is Q268X, a nonsense mutation in which a stop codon is created at amino acid 268. The result is a truncated, partially functional protein. Evidence suggests that the DNA binding domain remains intact; however, the functionality of the putative ligand binding domain is compromised [4]. Insulin release rate as well as acute insulin response is decreased in diabetic patients with the HNF4A (Q268X) mutation. Interestingly, this remains true in non-diabetic patients who have the HNF4A (Q268X) mutation [6,132]. Further studies demonstrate that there is no dominant negative effect of Q268X. Instead, the phenotypes in different tissues could be explained by dose dependent HNF4 [6]. Mutant E276Q is the truncated, 40 kDa form and is characterized by loss of transcriptional activity as well as loss of DNA binding activity. It is possible that truncated HNF4A (E276Q) exhibits loss of function due to heterodimerization with the wildtype HNF4A protein. Thus, the amount of functional wildtype homodimers is diminished [6].

MODY1 was found to have a distinguished lipoprotein profile compared to other forms of diabetes. HNF4A is a key regulator of the ACAT2 promoter which is located in the liver and is responsible for catalyzing the formation of cholesteryl esters in hepatic VLDL assembly [4]. Many transcription factors are downstream of HNF4A. In the event of mutations in HNF4A, pancreatic transcription factors are upregulated in MODY1 cells.
This may indicate the presence of a compensatory mechanism aimed to overcome haploinsufficiency caused by mutations in HNF4A. Putative HNF4A downstream target genes are more affected by the decrease in HNF4A levels if: (1) they contain multiple binding sites for HNF4A, (2) the distribution of binding sites is in proximity to the transcription start site of the target gene, and (3) they harbor fewer motifs for other transcription factors in their promoters. These molecular features influence the sensitivity of target genes and their ability to bind to HNF4A [6,132]. Patients with MODY1 are clinically characterized primarily by mild hyperglycemia [3,40]. Effective treatments for MODY1 patients are sulfonylureas and insulin [134].

2.2. GCK-MODY (MODY2)

Mutations in the central glycolytic enzyme glucokinase (GCK) gene can result in the development of MODY2 [1,2,135]. The structure of glucokinase consists of a large and a small domain separated by a deep opening where glucose binds [1,2,81,135]. GCK mutations have been found throughout the peptide structure that affect the enzymatic behavior but to different levels depending on the position and type of amino acid. Two regions that have a critical role during the conformational change observed in the active and inactive form are helices α13 and α5. So far, more than 620 GCK gene mutations have been reported in over 1400 patients with GCK-MODY. Most mutations are spread over ten exons of the gene which encode the pancreatic beta cell isoform of glucokinase [1,81,135]. MODY 2 is associated with heterozygous inactivating mutations in the GCK gene, which maps to chromosome 7 and spans 12 exons. The GCK gene encodes a glucokinase enzyme that plays a vital role in glucose metabolism. The kinetics differ from other hexokinases because of its lower affinity for glucose. GCK can have increased or decreased binding affinity to glucose depending on the type of mutation [2,33,136,137]. Missense, nonsense, frameshift, and splice site mutations have been reported, which are distributed throughout the 10 exons encoding the pancreatic β-cell isoform of the enzyme. As of now, there are no discovered mutational hot spots. Over 250 mutations have been reported in more than one family. In pancreatic β cells, the enzyme normally acts as a glucose sensor and regulates insulin secretion [33,137]. Activating mutations in the glucokinase gene (GCK) can cause hyperglycemia whereas inactivating mutations results in hypoglycemia [1,81,135]. Heterozygous inactivating mutations cause GCK–MODY. All inactivating mutations are associated with mild fasting hyperglycemia while other specific symptoms are missing. Therefore, GCK-MODY is likely to be underdiagnosed. Luckily, several GCK mutations have been genetically and functionally characterized which helped elucidate the link between mutation and function. Notably, the p. Gly68Val mutation causes structural conformational changes that lead to loss of function in the ability to bind glucose and ATP (Table 1) [34].

A single nucleotide mutation can induce a conformational change and affect the functionality of all components in the glucokinase enzymatic pathway. Inactivating and activating GCK mutations affect the mechanistic properties of this glucose sensor. With GCK mutations in particular, it is difficult to relate the mutations to clinical manifestations as it relates to insulin release and insulin resistance [1,33,81,136,137]. Patients with MODY2 with type 2 diabetes are clinically characterized by mild hyperglycemia (Table 1) [5]. Treatment of MODY2 is clinically unnecessary (Table 2) [130].

2.3. HNF1A-MODY 3

MODY3 is caused by mutations in the HNF1A gene. The protein product is localized to the liver, kidney, intestine, and pancreatic beta cells. It is thought to work in a hierarchical fashion, controlling the expression of insulin genes in mature beta cells. Additionally, HNF1A is proposed to control glucose transport genes (GLUT2) [9,138,139]. The two most common types of mutations associated with MODY3 are missense mutations which prevail in the dimerization and DNA binding domain of HNF1A and truncating mutations which are predominant in the transactivating domain [8,9,138]. Three novel mutations have been discovered (p.R171G, p.G245R, and p.R263H) (Table 1) [38] which reduce transcriptional
activity and reduce nuclear localization. It is postulated that this occurs due to disruption of the three-dimensional structure of the protein product. A more common variant of HNF1A is p.S487N which results in loss-of-function and a more severe phenotype. Patients expressing these mutations oftentimes have transient neonatal hyperinsulinemia hypoglycemia, progressive hypoglycemia throughout childhood, gradual decrease in insulin secretion, and diagnosis with diabetes mellitus before the age of 25 [8,138,139].

2.4. PDX1-MODY (MODY4)

Genetic mutations in the pancreatic and duodenal homeobox 1 (PDX1) gene can contribute to MODY4. PDX1 is located on chromosome 7 and codes for an N-terminal transactivation domain, a homeodomain responsible for DNA binding and nuclear localization domain. It also codes for a conserved C-terminus that is often mutated in MODY4 [140,141]. PDX1 is a homeodomain-containing transcription factor, which regulates insulin gene expression, and is necessary for proper beta cell pancreatic development and function as well as the regulation of genes that code for glucagon, glucose transporter 2 (GLUT2), and other glucokinase enzymes [140,142-145]. PDX1 mutations can result in impaired expression of insulin and GLUT2 [145,146], permanent neonatal diabetes [89,147], and exocrine pancreatic insufficiency [146].

In vitro functional studies reveal that a single nucleotide substitution change of CCT to ACT at codon 33 resulted in a Pro to Thr substitution (P33T) in the IPF1 transactivation domain. P33T mutations were later determined to complicate pregnancies, where it is very likely for carriers of this mutation to develop gestational diabetes and give birth to underweight babies [140,148]. Patients with PDX1–MODY with type 2 diabetes have been shown to be effectively treated with metformin, dipeptidyl peptidase–4 inhibitors, and insulin, which are all options for treating individuals with MODY 4 in case reports [29,78,89].

2.5. HNF1B-MODY (MODY5)

MODY5 is caused by mutations in the hepatocyte nuclear factor-1β (HNF1B) gene; the HNF1B protein product is found in many organs and tissues including the lungs, liver, intestine, and pancreas [12,30]. The HNF1B functions in the development of renal nephrons and embryonic pancreas development. Mutation in the HNF1B gene can result in severe non-diabetic renal disease, glomerulocystic kidney disease, and hyperglycemia (Table 1) [42–48]. HNF1B is located on chromosome 17q12 and comprises nine coding exons. Fifty percent of patients with MODY5 have a whole gene deletion of HNF1B which is associated with severe pathology, elevated HbA1c, hyperglycemia, and decreased insulin secretion with progressive pancreatic β cell dysfunction (Table 2) [12,30,134].

Several mutations are associated with renal abnormalities and MODY5 in particular (Table 1). Molecular studies also reveal a frameshift mutation (c.C2304del) results in a truncated protein which affects the transactivated protein domain. This novel mutation is found to interact with, and have negative influence on, PKD2 and SOCS3, which play a role in renal abnormalities such as renal cysts and early diabetes onset [149]. Patients with HNF1B–MODY have been shown to be effectively treated with sulfonylurea [150], repaglinide [30], GLP-1 RA [93], and insulin in case reports (Table 2).

2.6. NEUROD1-MODY (MODY6)

MODY6 is caused by heterozygous mutations in the NEUROD1 gene, mapping to the chromosomal location 2q32. MODY6 is considered low penetrant. It is thought that the development of the disease is affected by genetic modifying factors such as epigenetics, environmental factors, and their interaction. NEUROD1 is a type II basic helix loop helix (bHLH) transcription factor with expression in pancreatic islet cells, intestine, and a subset of neurons in the central and peripheral nervous system. NEUROD1 is shown to interact with promoter regions and proteins. It can bind and activate the promoter of the sulfonylurea receptor 1 (SUR1), glucokinase (GCK), and PAX6. When these components are properly functioning together, normal glucose homeostasis is maintained [151–153].
Currently, 16 missense or truncated mutations of NEUROD1 have been genetically characterized, most of which are located in the bHLH or transactivation domain. Mutations in NEUROD1 manifest clinically in similar ways with a wide variety of affected functions. The mutations are associated with nephropathy, low C–peptide, high hba1c, diabetic ketoacidosis, neurological abnormality, and in severe cases, renal failure [152–154]. Patients with MODY6 are clinically characterized by adult onset of the disease. Effective treatment of MODY6 is accomplished via insulin [130].

2.7. KLF11-MODY (MODY7)

KLF11 is an SP/Kruppel-like transcription factor which is mutated in MODY7. The function of Kruppel-like factor 11 is conserved in most species [51,155]. The KLF11 gene encodes for a transcriptional factor that regulates pancreatic β-cell function and impairment of insulin secretion (Table 2). Four missense mutations (R29Q, Q62R, T220M, and A347S) have been identified as associated with the development of diabetes [51,54]. KLF11 can also bind to GC-rich sites in the promoter region of the human insulin (INS) gene and inhibits the expression of INS. KLF11 binds and interacts with a host of epigenetic repressors including histone deacetylase 4 (HDAC4), Chromobox 5 (CBX5: HP1α), and Histone methyltransferase (HMT: SUV39H1), as well as a transcriptional repressor, SIN3A [15,17,51,53,156].

Interestingly, functional studies and co-immunoprecipitation assays reveal that KLF11 and PDX1 interact with one another to activate. This suggests that there is a hierarchical regulatory cascade for these two genes involved in development of MODY [53]. One genetic variant of KLF11, A347S has been extensively studied and is revealed to affect transcriptional regulatory domain 3 (TRD3) [51]. With this variant, the binding is disrupted due to the mutation affecting the transcriptional regulatory domain 3 (TRD3) [15,17,51,54,156]. Patients with MODY7 are clinically characterized by pancreatic malignancy. Effective treatment of MODY7 is accomplished via insulin [130].

2.8. CEL-MODY (MODY8)

MODY8 is associated with mutations in the enzyme carboxyl ester lipase (CEL). It is also known as bile salt-dependent lipase or bile salt-stimulated lipase. It hydrolyzes fat-soluble vitamins, dietary fat, and cholesteryl esters in the duodenum. CEL is primarily expressed in pancreatic acinar cells and secondarily in lactating mammary glands [157]. CEL maps to the chromosomal location 9q34.3 and contains a carriable number of tandem repeats (VNTR) region that encodes a mucin-like protein tail. In MODY8, single-base pair deletions in the first VNTR repeat are the cause for disease state and pancreatic dysfunction, such as pancreatic lipomatosis and pancreatic cysts. This finding suggests that MODY8 can also be categorized as a protein misfolding disease. The C–terminal region of the CEL gene consists of an 11 amino acid repeat, trailed by the unique sequence KEAQMPAVIRF. Due to the variability in number of C-terminal repeats in the general population and the CEL gene’s general polymorphism, CEL is an excellent candidate gene for further studies [18,158].

Several mutations are identified as being associated with the development of diabetes (Table 1) [97]. Recently, two more novel single-base pair deletion CEL mutations have been identified, (c.168delT) and (c.1685delC), both of which have been associated with MODY8. Both occur on the VNTR segment of CEL, shift the reading frame, and prematurely truncate the splice variant at segment 13 of the VNTR sequence [158]. Upon examining the probands and their families, this mutation was associated with dominantly inherited insulin-dependent diabetes, pancreatic exocrine dysfunction, atrophic pancreas with lipomatosis, and pancreatic cysts [18,158]. Management of MODY8 includes dietary, oral antidiabetic, or insulin interventions (Table 2).

2.9. PAX4-MODY (MODY9)

MODY9 is caused by mutations in the gene encoding Paired box 4 (PAX4) transcription factor, which is essential for insulin production and pancreatic β-cell differentiation, devel-
opment, and maintenance. PAX4 expression has also been linked to regulating pancreatic β–cell survival [159] and correlates with improved survival of pancreatic β–cells and a higher resistance to cytokine-induced apoptosis [160,161].

Several mutations have been identified as being associated with the development of nephrological diseases (Table 1). PAX4 (p.Q250del) was extensively studied and was found to have a disrupted splice site within exon 8. The result is a three-nucleotide deletion at position 250. When expressed in HEK 293 cells, both (p.Q250del) and wildtype PAX4 were found to normally translocate to the nucleus of β–cells. However, in the case of (p.Q250del), expression of the human insulin and glucagon promoter was inefficient compared to the wildtype [162]. Thus, the (p.Q250del) mutation impairs the PAX4 repressor functions on target-gene promoters (such as insulin and glucagon). It is also suggested that PAX4 mutations increase susceptibility to apoptosis in high glucose conditions [162]. Treatment of MODY9 is effectively managed by OHAs and insulin (Table 2) [130].

2.10. INS-MODY (MODY10)

MODY10 is caused by mutations to the insulin (INS) gene. The INS gene encodes preproinsulin that is targeted to and translocated across the endoplasmic reticulum membrane. The identification of mutations within INS shows an association with neonatal hypoglycemia (Table 1). Mutations in the INS gene can lead to defects in nuclear factor Kappa–light–chain–enhancer of activated B cells (NF-kB). Clinical manifestation of mutations in INS include decreased β–cells mass, gradual loss of insulin secretion, and variable-onset diabetes mellitus including neonatal diabetes (Table 2) [163]. Heterozygous missense mutations in INS can lead to protein misfolding, protein aggregates, ER stress, and increased rate of apoptosis. Homozygous mutations of INS are associated with loss-of-function and decreased insulin biosynthesis by gene deletion. They lack translation initiation signaling and have altered mRNA stability (faster degradation). Certain INS mutations can lead to a more than 80% decrease in insulin production. Interestingly, homozygous mutations of INS represent 20% of total mutations in the gene [109,163–165]. Patients with MODY10 are clinically characterized by neonatal hypoglycemia (Table 1). Effective treatment of MODY10 is managed by insulin (Table 2) [130].

2.11. BLK-MODY (MODY11)

MODY11 is linked to heterozygous mutations in the tyrosine-protein kinase (BLK) gene belonging to the SRC proto-oncogene family. It encodes a tyrosine receptor protein which stimulates pancreatic beta cells to produce and secrete insulin. BLK is located on human chromosome 8p23–p22 and encodes a 505 length amino acid protein [112]. Unlike other subtypes of MODY, BLK–MODY is not highly penetrant; instead, it is described as having incomplete penetrance, meaning that several BLK mutations do not directly or necessarily cause diabetes (although they are still pathogenic). One such example of incomplete penetrance is the p.A71T mutation. It is a loss–of–function mutation which is shown to abolish the enhancing effect of BLK on insulin content and secretion from pancreatic beta cells [112]. The p.A71T loss–of–function mutation has a weak correlation with diabetes generally, although it may be “diabetogenic” in obese or overweight patients bearing the mutation [112]. MODY11 is effectively treated by OHAs and insulin (Table 2) [130].

2.12. ABCC8-MODY (MODY12)

MODY12 is caused by heterozygous mutations in the ATP binding cassette subfamily C member 8 (ABCC8) gene. ABCC8 encodes sulfonyl-urea receptor 1 (SUR1), a subunit of ATP-sensitive channels found in pancreatic beta cell membranes. ABCC8 is highly correlated with secretion of insulin and regulating blood glucose levels. Notably, mutations in ABCC8 are linked to congenital hyperinsulinism [66,120,150,166]. Patients with ABCC8-MODY can sometimes be underweight and present with hypoglycemia although other patients can have opposite complications [114].
Over 125 ABCC8 mutations have been found; 28 of these mutations have been extensively studied and summarized thus far, 25 of which are missense mutations, 1 a splicing mutation, 1 a small deletion, and 1 a small insertion [65]. The missense mutation p.Gly826Asp leads to increased fasting plasma glucose levels, hyperglycemia, and increased ABCC8 protein concentration (Table 1). Mutations in ABCC8 directly affect insulin secretion and ATP-sensitive potassium channel dysfunction (Table 2). Abnormal insulin secretion leads to glucose metabolism disorder [65]. ABCC8 mutations also lead to increased ABCC8 protein concentrations due to inhibition of the protein degradation pathway. Mutation p.Gly826Asp specifically has been shown to block both the ubiquitination and autophagy lysosome degradation pathway [65]. Patients with MODY12 are clinically characterized by renal diabetes (Table 1). MODY12 is effectively treated with insulin and sulfonylureas (Table 2) [130].

2.13. KCNJ11-MODY (MODY13)

MODY13 is caused by heterozygous mutations in the potassium inwardly rectifying channel subfamily J member 11 gene. KCNJ11 is mapped to chromosome 11p15.1. This gene encodes for pancreatic beta cell inwardly rectifier (BIR). More importantly, it encodes the Kir6.2 subunit of the adenosine triphosphate sensitive potassium (KATP) channel, which plays a key role in insulin secretion. Several mutations in the KCNJ11 gene are associated with renal diabetes, hyperinsulinemic hyperglycemia and neonatal diabetic phenotypes (Tables 1 and 2) [70].

Mutation p.E322K has severe effects and is associated with permanent neonatal diabetes mellitus and causes convulsions due to extreme hypoglycemia. Neurological abnormalities (such as developmental delays, autism, ADHD, sleep disorders, and seizures) are also reported in p.E322K and other KCNJ11 mutations (Table 1). Not all mutations show severe clinical manifestations. Mutation p.E227G is associated with penetrance of hyperglycemia in family members with the mutation. It is also linked with transient neonatal diabetes [70]. Patients with MODY13 are clinically characterized by renal diabetes, hyperinsulinemic hypoglycemia, and neonatal diabetes (Table 1). MODY13 is effectively treated with sulfonylureas (Table 2) [130].

2.14. APPL-MODY (MODY14)

MODY14 is caused by mutations in the adaptive protein phosphotyrosine interacting with PH domain and leucine zipper 1 (APPL1) gene. APPL1 is responsible for regulating cell proliferation and interaction between adiponectin and insulin signaling pathways. In tissues where APPL1 mutated proteins are highly expressed, premature apoptosis is more likely to occur. Overexpression also causes dysmorphic phenotypes and developmental delays [77].

APPL1 binds to AKT2 (RAC-beta serine/threonine-protein kinase or AKT serine/threonine kinase 2). AKT2 is a key molecule in the insulin signaling pathway. APPL1 can enhance insulin-induced AKT2 activation and downstream signaling in the liver, skeletal muscle, adipocytes, and endothelium. APPL1 potentiates the inhibitory effect of insulin on hepatic gluconeogenesis through activation of AKT protein kinase [77]. The p.Leu552Ter is a missense mutation which results in premature truncation and a deletion of most of the phosphotyrosine binding (PTB) domain, resulting in diminished insulin-induced downstream signaling in target tissues (Table 2) [77]. Patients with MODY14 are clinically characterized by Wolfram or DIDMOAD syndrome (Table 1). MODY14 is effectively treated with OHAs or insulin (Table 2) [130].

3. Conclusions

MODY is a rare form of diabetes that is difficult both to diagnose and to characterize. Clinical manifestations of the disease resemble those of T1DM and T2DM. This is also complicated by subtypes of MODY which are of low penetrance. The subtypes of MODY are caused by specific mutations in various genes with widely different functions. These
various mutated genes can exert repressive or activating influence on transcriptional pathways, and thus can influence the function of target tissues. Genetic mutations in all MODY subtypes are well associated with diabetic phenotypes (hyperglycemia and hypoinsulinemia). However, recently, Laver et al. reported that variants in BLK, PAX4, and KLF11 are not causative of MODY [166]. Moreover, some subtypes are not only linked with diabetes, but also with pancreatic, renal, or neurological pathologies. More functional studies and characterizations (e.g., β cell function and insulin resistance) for each mutated MODY subtype will offer pathogenic mechanisms, which will lead to the development of diagnostic tools and therapeutic approaches for a variety of MODY subtypes.

**Author Contributions:** Writing—original draft preparation, H.Y. and S.E.H.; writing—review and editing, A.V., S.E.H., B.G.J. and S.R.; funding acquisition, S.R. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was funded by RosVivo Therapeutics (AWD-01-00003158 to S.R.).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** S.R. is an employee and a member of the board of directors of RosVivo Therapeutics. S.E.H. is a member of the board of directors of RosVivo Therapeutics.

**References**

1. George, D.C.; Chakraborty, C.; Haneef, S.A.; Nagasundaram, N.; Chen, L.; Zhu, H. Evolution- and structure-based computational strategy reveals the impact of deleterious missense mutations on MODY 2 (maturity-onset diabetes of the young, type 2). *Theranostics* 2014, 4, 366–385. [CrossRef]
2. Langer, S.; Platz, C.; Waterstradt, R.; Baltrusch, S. Characterization of two MODY2 mutations with different susceptibility to activation. *Biochem. Biophys. Res. Co.* 2015, 464, 1113–1119. [CrossRef] [PubMed]
3. Kim, K.A.; Kang, K.; Chi, Y.I.; Chang, J.; Lee, M.K.; Kim, K.W.; Shoelson, S.E.; Lee, M.S. Identification and functional characterization of a novel mutation of hepatocyte nuclear factor-1alpha gene in a Korean family with MODY3. *Diabetologia* 2003, 46, 721–727. [CrossRef] [PubMed]
4. Pramfalk, C.; Karlsson, E.; Groop, L.; Rudel, L.L.; Angelin, B.; Eriksson, M.; Parini, P. Control of ACAT2 liver expression by HNF4{	extalpha}: Lesson from MODY1 patients. *Arter. Thromb. Vasc. Biol.* 2009, 29, 1233–1241. [CrossRef] [PubMed]
5. Ma, Y.; Han, X.; Zhou, X.; Li, Y.; Gong, S.; Zhang, S.; Cai, X.; Zhou, L.; Luo, Y.; Li, M.; et al. A new clinical screening strategy and prevalence estimation for glucokinase variant-induced diabetes in an adult Chinese population. *Genet. Med.* 2019, 21, 939–947. [CrossRef]
6. Stoffel, M.; Duncan, S.A. The maturity-onset diabetes of the young (MODY1) transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism. *Proc. Natl. Acad. Sci. USA* 1997, 94, 13209–13214. [CrossRef] [PubMed]
7. Kapoor, R.R.; Locke, J.; Colclough, K.; Wales, J.; Conn, J.J.; Hattersley, A.T.; Ellard, S.; Hussain, K. Persistent hyperinsulinemic hypoglycemia and maturity-onset diabetes of the young due to heterozygous HNF4A mutations. *Diabetes* 2008, 57, 1659–1663. [CrossRef]
8. Lehto, M.; Tuomi, T.; Mahtani, M.M.; Widen, E.; Forsblom, C.; Sarelin, L.; Gullstrom, M.; Isomaa, B.; Lehtovirta, M.; Hyyrkko, A.; et al. Characterization of the MODY3 phenotype Early-onset diabetes caused by an insulin secretion defect. *J. Clin. Invest.* 1997, 99, 582–591. [CrossRef]
9. Behl, R.; Malhotra, N.; Joshi, V.; Poojary, S.; Middha, S.; Gupta, S.; Olaonipekun, A.B.; Okoye, I.; Wagh, B.; Biswas, D.; et al. Meta-analysis of HNF1A-MODY3 variants among human population. *J. Diabetes Metab. Dis.* 2022, 21, 1037–1046. [CrossRef] [PubMed]
10. Macfarlane, W.M.; Frayling, T.M.; Ellard, S.; Evans, J.C.; Allen, L.I.; Bulman, M.P.; Ayres, S.; Shepherd, M.; Clark, P.; Millward, A.; et al. Missense mutations in the insulin promoter factor-1 gene predispose to type 2 diabetes. *J. Clin. Invest.* 1999, 104, R33–R39. [CrossRef] [PubMed]
11. Pruhova, S.; Dusatková, P.; Sumník, Z.; Kolousková, S.; Pedersen, O.; Hansen, T.; Cinek, O.; Lebl, J. Glucokinase diabetes in 103 families from a country-based study in the Czech Republic: Geographically restricted distribution of two prevalent GCK variants. *Pediatr. Diabetes* 2010, 11, 529–535. [CrossRef] [PubMed]
12. Bustamante, C.; Sanchez, J.; Seehervung, T.; Ukarapong, S. Early Onset of Mody5 Due to Haploinsufficiency of Hnf1b. *AACE Clin. Case. Rep.* 2020, 6, e243–e246. [CrossRef] [PubMed]
13. Wang, C.; Fang, Q.; Zhang, R.; Lin, X.; Xiang, K. Scanning for MODY5 gene mutations in Chinese early onset or multiple affected diabetes pedigrees. *Acta Diabetol.* 2004, 41, 137–145. [CrossRef] [PubMed]
14. Haliyur, R.; Tong, X.; Sanyoura, M.; Shrestha, S.; Lindner, J.; Saunders, D.C.; Aramandla, R.; Poffenberger, G.; Redick, S.D.; Bottino, R.; et al. Human islets expressing HNF1A variant have defective beta cell transcriptional regulatory networks. *J. Clin. Invest.* 2019, 129, 246–251. [CrossRef] [PubMed]

15. Lomberk, G.; Mathison, A.J.; Grzenda, A.; Seo, S.; DeMars, C.J.; Rizvi, S.; Bonilla-Velez, J.; Calvo, E.; Fernandez-Zapico, M.E.; Iovanna, J.; et al. Sequence-specific recruitment of heterochromatin protein 1 via interaction with Kruppel-like factor 11, a human transcription factor involved in tumor suppression and metabolic diseases. *J. Biol. Chem.* 2012, 287, 13026–13039. [CrossRef]

16. Kato, T.; Tanaka, D.; Muro, S.; Jambaljav, B.; Mori, E.; Yonemitsu, S.; Oki, S.; Inagaki, N. A Novel p.L145Q Mutation in the HNF1B Gene in a Case of Maturity-onset Diabetes of the Young Type 5 (MODY5). *Intern. Med.* 2018, 57, 2035–2039. [CrossRef]

17. Ushijima, K.; Narumi, S.; Ogata, T.; Yokota, I.; Sugihara, S.; Kaname, T.; Horikawa, Y.; Matsubara, Y.; Fukami, M.; Kawamura, T.; et al. KLF11 variant in a family clinically diagnosed with early childhood-onset type 1B diabetes. *Pediatr. Diabetes* 2019, 20, 712–719. [CrossRef]

18. El Jellas, K.; Dusatkova, P.; Haldorsen, I.S.; Molnes, J.; Tfjora, E.; Johansson, B.B.; Fjeld, K.; Johansson, S.; Pruhova, S.; Groop, L.; et al. Two New Mutations in the CEL Gene Causing Diabetes and Hereditary Pancreatitis: How to Correctly Identify MODY8 Cases. *J. Clin. Endocrinol. Metab.* 2022, 107, e1455–e1466. [CrossRef]

19. Xu, J.Y.; Chan, V.; Zhang, W.Y.; Wat, N.M.; Lam, K.S. Mutations in the hepatocyte nuclear factor-1alpha gene in Chinese MODY families: Prevalence and functional analysis. *Diabetologia* 2002, 45, 744–746. [CrossRef]

20. Ma, Y.; Gong, S.; Wang, X.; Cai, X.; Xiao, X.; Gu, W.; Yang, J.; Zhong, L.; Xiao, J.; Li, M.; et al. New clinical screening strategy to distinguish HNF1A variant-induced diabetes from young early-onset type 2 diabetes in a Chinese population. *BMJ Open Diabetes Res. Care* 2020, 8, e000745. [CrossRef]

21. De Leon, D.D.; Stanley, C.A. Permanent Neonatal Diabetes Mellitus. In *GeneReviews(R)*; Adam, M.P., Everman, D.B., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Gripp, K.W., Amemiya, A., Eds.; University of Washington: Seattle, WA, USA, 1993.

22. Horikawa, Y. Maturity-onset diabetes of the young as a model for elucidating the multifactorial origin of type 2 diabetes mellitus. *J. Diabetes Investig.* 2018, 9, 704–712. [CrossRef] [PubMed]

23. Gaal, Z.; Szucs, Z.; Kantor, I.; Luczay, A.; Toth-Heyn, P.; Benn, O.; Felszeghy, E.; Karadi, Z.; Madar, L.; Balogh, I. A Comprehensive Analysis of Hungarian MODY Patients-Part I: Gene Panel Sequencing Reveals Pathogenic Mutations in HNF1A, HNF1B, HNF4A, ABC8 and INS Genes. Life (Basel) 2021, 11, 755. [CrossRef] [PubMed]

24. Fajans, S.S.; Brown, M.B. Administration of sulfonylureas can increase glucose-induced insulin secretion for decades in patients with maturity-onset diabetes of the young. *Diabetes Care* 1993, 16, 1254–1261. [PubMed]

25. Becker, M.; Galler, A.; Raile, K. Meglitinide analogues in adolescent patients with HNF1A-MODY (MODY 3). *Pediatrics* 2014, 133, e775–e779. [CrossRef] [PubMed]

26. Ostoft, S.H.; Bagger, J.I.; Hansen, T.; Pedersen, O.; Faber, J.; Holst, J.J.; Knop, F.K.; Vilsboll, T. Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: A double-blind, randomized, crossover trial. *Diabetes Care* 2014, 37, 1978–1985. [CrossRef]

27. Rose, K.; Christiansen, A.S.; Storgaard, H.; Haedersdal, S.; Hansen, T.; Knop, F.K.; Vilsboll, T. Diagnosis and treatment of maturity onset diabetes of the young type 3. *Ugeskr. Laeger.* 2018, 180, 6.

28. Park, G.M.; Lee, S.J.; Seo, J.Y.; Lim, K.I. A case of maturity-onset diabetes of the young type 4 in Korea. *Ann. Pediatr. Endocrinol. Metab.* 2022. [CrossRef]

29. Mangrum, C.; Rush, E.; Shivashawmaya, V. Genetically Targeted Dipeptidyl Peptidase-4 Inhibitor Use in a Patient with a Novel Mutation of MODY type 4. *Clin. Med. Insights. Endocrinol. Diabetes* 2015, 8, 83–86. [CrossRef]

30. Roehlen, N.; Hilger, H.; Stock, F.; Glaser, B.; Guhl, J.; Schmitt-Graeff, A.; Seufert, J.; Laubner, K. 17q12 Deletion Syndrome as a Rare Cause for Diabetes Mellitus Type MODYS. *J. Clin. Endocrinol. Metab.* 2018, 103, 3601–3610. [CrossRef]

31. Yamagata, K.; Furuta, H.; Oda, N.; Kaisaki, P.J.; Menzel, S.; Cox, N.J.; Fajans, S.S.; Signorini, S.; Stoffel, M.; Bell, G.I. Mutations in the hepatocyte nuclear factor-α gene in maturity-onset diabetes of the young (MODY1). *Nature 1996*, 384, 458–460. [CrossRef]

32. Cho, E.H.; Min, J.W.; Choi, S.S.; Choi, H.S.; Kim, S.W. Identification of Maturity-Onset Diabetes of the Young Caused by Glucokinase Mutations Detected Using Whole-Exome Sequencing. *Endocrinol. Metab. (Seoul)* 2017, 32, 296–301. [CrossRef] [PubMed]

33. Gutierrez-Nogues, A.; Garcia-Herrero, C.M.; Oriola, J.; Vincent, O.; Navas, M.A. Functional characterization of MODY2 mutations in the nuclear export signal of glucokinase. *Biochim. Biophys. Acta Mol. Basis Dis.* 2018, 1864, 2385–2394. [CrossRef] [PubMed]

34. Wabitsch, M.; Lahr, G.; Van de Bunt, M.; Marchant, C.; Lindner, M.; von Puttkamer, J.; Fenneberg, A.; Debatin, K.M.; Klein, R.; Ellard, S.; et al. Heterogeneity in disease severity in a family with a novel G68V GCK activating mutation causing persistent hyperinsulinemic hypoglycaemia of infancy. *Diabetes Med.* 2007, 24, 1393–1399. [CrossRef] [PubMed]

35. Capuano, M.; Garcia-Herrero, C.M.; Tinto, N.; Carluccio, C.; Capobianco, V.; Coto, I.; Cola, A.; Iafusco, D.; Franzese, A.; Zagari, A.; et al. Glucokinase (GCK) mutations and their characterization in MODY2 children of southern Italy. *PLoS ONE* 2012, 7, e38906. [CrossRef] [PubMed]

36. Langer, S.; Waterstradt, R.; Hillebrand, G.; Santer, R.; Baltusch, S. The novel GCK variant p.Val455Leu associated with hyperinsulinism is susceptible to allosteric activation and is conducive to weight gain and the development of diabetes. *Diabetologia* 2021, 64, 2687–2700. [CrossRef] [PubMed]
105. Tiwari, P. Recent Trends in Therapeutic Approaches for Diabetes Management: A Comprehensive Update. J. Diabetes Res. 2015, 2015, 340838. [CrossRef]

106. Baboon, D.; Saarimaki-Vire, J.; Borshagovski, D.; Survila, M.; Lindholm, P.; Galli, E.; Eurola, S.; Ustinov, J.; Gryn, H.; Huopio, H.; et al. Insulin mutations impair beta-cell development in a patient-derived iPSC model of neonatal diabetes. Elife 2018, 7, e38519. [CrossRef]

107. Wang, J.; Takeuchi, T.; Tanaka, S.; Kubo, S.K.; Kayo, T.; Lu, D.; Takata, K.; Koizumi, A.; Izumi, T. A mutation in the insulin 2 gene induces diabetes with severe pancreatic beta-cell dysfunction in the Mody mouse. J. Clin. Invest. 1999, 103, 27–37. [CrossRef]

108. Nishi, M.; Nanjo, K. Insulin gene mutations and diabetes. J. Diabetes Investig. 2011, 2, 92–100. [CrossRef]

109. Shaikh, A.A.; Shirah, B.; Alzelaye, S. A homozygous mutation in the insulin gene (INS) causing autosomal recessive neonatal diabetes in Saudi families. Ann. Pediatr. Endocrinol. Metab. 2020, 25, 42–45. [CrossRef]

110. Cascais, M.; Pereira, E.; Vieira, A.; Venancio, M.; Ramos, L.; Moleiro, P. Hyperglycemia in pediatric age: Could it be maturity onset diabetes of the young? Case reports and review of the literature. Ann. Pediatr. Endocrinol. Metab. 2019, 24, 262–266. [CrossRef]

111. Kettunen, J.L.T.; Tuomi, T. Human Physiology of Genetic Defects Causing Beta-cell Dysfunction. J. Mol. Biol. 2020, 432, 1579–1598.

112. Bonnefond, A.; Yengo, L.; Philippe, J.; Dechaume, A.; Ezzidi, I.; Vaillant, E.; Gjesing, A.P.; Andersson, E.A.; Czernichow, S.; Hercberg, S.; et al. Reassessment of the putative role of BLK-p.A71T loss-of-function mutation in MODY and type 2 diabetes. Diabetologia 2013, 56, 492–496. [CrossRef] [PubMed]

113. Ferrer, J. A genetic switch in pancreatic beta-cells: Implications for differentiation and haploinsufficiency. Diabetes 2002, 51, 2355–2362. [CrossRef] [PubMed]

114. Zhang, Y.; Hu, S.; Huang, H.; Liu, J. A case report of Maturity-onset diabetes of the young 12: Large fragment deletion in ABCC8 gene with literature review. Ann. Transl. Med. 2022, 10, 378. [CrossRef] [PubMed]

115. Yan, F.F.; Lin, Y.W.; MacMullen, C.; Ganguly, A.; Stanley, C.A.; Shyng, S.L. Congenital hyperinsulinism associated ABCC8 mutations that cause defective trafficking of ATP-sensitive K+ channels: Identification and rescue. Diabetes 2007, 56, 2339–2348. [CrossRef] [PubMed]

116. Lang, V.; Light, P.E. The molecular mechanisms and pharmacotherapy of ATP-sensitive potassium channel gene mutations underlying neonatal diabetes. Pharmacogenomics Pers. Med. 2010, 3, 145–161. [PubMed]

117. Martin, G.M.; Rex, E.A.; Devaraneni, P.; Denton, J.S.; Boodhansingh, K.E.; DeLeon, D.D.; Stanley, C.A.; Shyng, S.L. Pharmacological Correction of Trafficking Defects in ATP-sensitive Potassium Channels Caused by Sulfonylurea Receptor 1 Mutations. J. Biol. Chem. 2016, 291, 21971–21983. [CrossRef]

118. Bohnen, M.S.; Ma, L.; Zhu, N.; Qi, H.; McLenaghan, C.; Gonzaga-Jauregui, C.; Dewey, F.E.; Overton, J.D.; Reid, J.G.; Shuldiner, A.R.; et al. Loss-of-Function ABCC8 Mutations in Pulmonary Arterial Hypertension. Circ. Genom. Precis Med. 2018, 11, e002087. [CrossRef] [PubMed]

119. Huang, Y.; Hu, D.; Huang, C.; Nichols, C.G. Genetic Discovery of ATP-Sensitive K(+) Channels in Cardiovascular Diseases. Circ. Arrhythm. Electrophysiol. 2019, 12, e007322. [CrossRef]

120. Malekizadeh, A.; Rahbaran, M.; Afshari, M.; Abbasi, D.; Aghaei Meybodi, H.R.; Hasanzad, M. Association of common genetic variants of KCNJ11 gene with the risk of type 2 diabetes mellitus. Nucl. Nucl. Nucleic Acids 2021, 40, 530–541. [CrossRef] [PubMed]

121. Gole, E.; Oikonomou, S.; Ellard, S.; De Franco, E.; Karavani, K. A Novel KCNJ11 Mutation Associated with Transient Neonatal Diabetes. J. Diabetes Res. 2018, 2018, 10, 175–178. [CrossRef]

122. Sachse, G.; Haythorne, E.; Hill, T.; Proks, P.; Joynson, R.; Terron-Exposito, R.; Bentley, L.; Tucker, S.J.; Cox, R.D.; Ashcroft, F.M. The KCNJ11-E23K Gene Variant Hastens Diabetes Progression by Impairing Glucose-Induced Insulin Secretion. Diabetes 2016, 7, 591–600. [CrossRef] [PubMed]

123. Malekizadeh, A.; Rahbaran, M.; Afshari, M.; Abbasi, D.; Aghaei Meybodi, H.R.; Hasanzad, M. Association of common genetic variants of KCNJ11 gene with the risk of type 2 diabetes mellitus. Nucl. Nucl. Nucleic Acids 2021, 40, 530–541. [CrossRef] [PubMed]

124. Gole, E.; Oikonomou, S.; Ellard, S.; De Franco, E.; Karavani, K. A Novel KCNJ11 Mutation Associated with Transient Neonatal Diabetes. J. Clin. Res. Pediatr. Endocrinol. 2018, 10, 175–178. [CrossRef]

125. Lin, Y.W.; MacMullen, C.; Ganguly, A.; Stanley, C.A.; Shyng, S.L. Congenital hyperinsulinism associated ABCC8 mutations that cause defective trafficking of ATP-sensitive K+ channels: Identification and rescue. Diabetes 2007, 56, 2339–2348. [CrossRef] [PubMed]

126. Lin, Y.W.; MacMullen, C.; Ganguly, A.; Stanley, C.A.; Shyng, S.L. Congenital hyperinsulinism associated ABCC8 mutations that cause defective trafficking of ATP-sensitive K+ channels: Identification and rescue. Diabetes 2007, 56, 2339–2348. [CrossRef] [PubMed]

127. Chistiakov, D.A.; Potapov, V.A.; Khodirev, D.C.; Shamkhalova, M.S.; Shestakova, M.V.; Nosikov, V.V. Genetic variations in the pancreatic ATP-sensitive potassium channel, beta-cell dysfunction, and susceptibility to type 2 diabetes. Acta Diabetol. 2009, 46, 43–49. [CrossRef]

128. Kim, S.H. Maturity-Onset Diabetes of the Young: What Do Clinicians Need to Know? Diabetes Metab. J. 2015, 39, 468–477. [CrossRef]
129. Urakami, T. Maturity-onset diabetes of the young (MODY): Current perspectives on diagnosis and treatment. *Diabetes Metab. Syndr. Obes.* 2019, 12, 1047–1056. [CrossRef]
130. Mitchell, M.W.; Moreno-De-Luca, D.; Myers, S.M.; Levy, R.V.; Turner, S.; Ledbetter, D.H.; Martin, C.L. 17q12 Recurrent Deletion Syndrome. In *GeneReviews(R)*; Adam, M.P., Everman, D.B., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Gripp, K.W., Amemiya, A., Eds.; University of Washington: Seattle, WA, USA, 1993.
131. Karlsson, E.; Shaat, N.; Groop, L. Can complement factors 5 and 8 and transthyretin be used as biomarkers for MODY 1 (HNF4A-MODY) and MODY 3 (HNF1A-MODY)? *Diabetes Med.* 2008, 25, 788–791. [CrossRef]
132. Sladek, F.M.; Dallas-Yang, Q.; Nepomuceno, L. MODY1 mutation Q268X in hepatocyte nuclear factor 4alpha allows for dimerization in solution but causes abnormal subcellular localization. *Diabetes* 1998, 47, 985–990. [CrossRef]
133. Herman, W.H.; Fajans, S.S.; Smith, M.J.; Polonsky, K.S.; Bell, G.I.; Halter, J.B. Diminished insulin and glucagon secretory responses to arginine in nondiabetic subjects with a mutation in the hepatocyte nuclear factor-4alpha/MODY1 gene. *Diabetes* 1997, 46, 1749–1754. [CrossRef] [PubMed]
134. Bonfig, W.; Hermanns, S.; Warncke, K.; Eder, G.; Engelsberger, I.; Burdach, S.; Ziegler, A.G.; Lohse, P. GCK-MODY (MODY 2) caused by a Novel p.Phe330Ser Mutation. *J. Pediatr.* 2011, 104, 676549. [CrossRef]
135. Shammas, C.; Neodeous, V.;_Phelan, M.M.; Lian, L.Y.; Skordis, N.; Phylactou, L.A. A report of 2 new cases of MODY2 and review of the literature: Implications for the type 2 diabetes drugs. *Metab. -Clin. Exp.* 2013, 62, 1535–1542. [CrossRef] [PubMed]
136. Bellanne-Chantelot, C.; Carette, C.; Riveline, J.P.; Valero, R.; Gautier, J.F.; Larger, E.; Reznik, Y.; Ducluzeau, P.H.; Sola, A.; Hartemann-Heurtier, A.; et al. The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3. *Diabetes* 2005, 57, 503–508. [CrossRef] [PubMed]
137. Valkovicova, T.; Skopkova, M.; Stanik, J.; Gasperiokova, D. Novel insights into genetics and clinics of the HNF1A-MODY. *Endocr. Regul.* 2019, 53, 110–134. [CrossRef] [PubMed]
138. Gragnoli, C.; Stanojevic, V.; Gori, A.; Von Preusshentzel, G.M.; Thomas, M.K.; Habener, J.F. IPF-1/MODY4 gene missense mutation in an Italian family with type 2 and gestational diabetes. *Metabolism* 2005, 54, 983–988. [CrossRef] [PubMed]
139. Yoshiji, S.; Horikawa, Y.; Kubota, S.; Enya, M.; Iwasaki, K.; Honjo, S.; Hosomichi, K.; et al. First Japanese Family With PDX1-MODY (MODY4): A Novel PDX1 Frameshift Mutation, Clinical Characteristics, and Implications. *J. Endocr. Soc.* 2022, 6, bvab159. [CrossRef]
140. Moede, T.; Leibiger, B.; Pour, H.G.; Berggren, P.; Leibiger, I.B. Identification of a nuclear localization signal, RRMKWKK, in the homeodomain transcription factor PDX-1. *FEBS Lett.* 1999, 461, 229–234. [CrossRef] [PubMed]
141. Stanojevic, V.; Yao, K.M.; Thomas, M.K. The coactivator Bridge-1 increases transcriptional activation by pancreas duodenum homebox-1 (PDX-1). *Mol. Cell Endocrinol.* 2005, 237, 67–74. [CrossRef]
142. Kim, S.K.; Selleri, L.; Lee, J.S.; Zhang, A.Y.; Gu, X.; Jacobs, Y.; Cleary, M.L. Pbx1 inactivation disrupts pancreas development and loss of the beta-cell phenotype and maturity onset diabetes. *Genes. Dev.* 1998, 12, 1763–1768. [CrossRef] [PubMed]
143. Jonsson, J.; Jonsson, L.; Simu, K.; Edlund, H. beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes mellitus. *Nat. Genet.* 2002, 30, 430–435. [CrossRef]
144. Ahlgren, U.; Jonsson, J.; Jonsson, L.; Edlund, H. Beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. *Nat. Genet.* 2002, 30, 430–435. [CrossRef]
145. Abreu, G.M.M.; Tarantino, R.M.; da Fonseca, A.C.P.; de Souza, R.B.; Soares, C.; Cabello, P.H.; Rodacki, M.; Zajdenverg, L.; Adam, M.P., Everman, D.B., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Gripp, K.W., Amemiya, A., Eds.; University of Washington: Seattle, WA, USA, 1993.
146. Bouchard, L.; Baracco, B.; Mantovani, V.; Pironi, L. NEUROD1 mutation in an Italian patient with maturity onset diabetes of the young 6: A case report. *BMC Endocr. Disord.* 2021, 21, 202. [CrossRef] [PubMed]
147. Horikawa, Y.; Enya, M.; Mabe, H.; Fukushima, K.; Takubo, N.; Ohashi, M.; Ikeda, F.; Hashimoto, K.I.; Watada, H.; Takeda, J. NEUROD1-deficient diabetes (MODY6): Identification of the first cases in Japanese and the clinical features. *Pediatr. Diabetes* 2018, 19, 236–242. [CrossRef] [PubMed]
148. Teramoto, S.; Aoki, T.; Reiner, M.; Sato, Y.; Fukuoka, J.; Hashimoto, K.I.; Watada, H.; Takeda, J. Identification of a novel mutation in the NEUROD1 gene in a Japanese patient with maturity onset diabetes of the young 6. *Diabetes Metab. Synth. Obes.* 2019, 12, 1047–1056. [CrossRef]
154. Sagen, J.V.; Baumann, M.E.; Salvesen, H.B.; Molven, A.; Sovik, O.; Njolstad, P.R. Diagnostic screening of NEUROD1 (MODY6) in subjects with MODY or gestational diabetes mellitus. Diabetes Med. 2005, 22, 1012–1015. [CrossRef] [PubMed]

155. Demirci, D.K.; Darendeliler, F.; Poyrazoglu, S.; Al, A.D.K.; Gul, N.; Tutuncu, Y.; Gultﬁdan, G.; Arga, K.Y.; Cacina, C.; Ozturk, O.; et al. Monogenic Childhood Diabetes: Dissecting Clinical Heterogeneity by Next-Generation Sequencing in Maturity-Onset Diabetes of the Young. OMICS 2021, 25, 431–449. [CrossRef] [PubMed]

156. Sun, Y.; Qu, J.; Wang, J.; Zhao, R.; Wang, C.; Chen, L.; Hou, X. Clinical and Functional Characteristics of a Novel KLF11 Cys354Phe Variant Involved in Maturity-Onset Diabetes of the Young. J. Diabetes Res. 2021, 2021, 7136869. [CrossRef]

157. Johansson, B.B.; Fjeld, K.; El Jellas, K.; Gravdal, A.; Dalva, M.; Tjora, E.; Raeder, H.; Kulkarni, R.N.; Johansson, S.; Njolstad, P.R.; et al. The role of the carboxyl ester lipase (CEL) gene in pancreatic disease. Pancreatology 2018, 18, 12–19. [CrossRef]

158. Brun, T.; Franklin, L.; St-Onge, L.; Biason-Lauber, A.; Schoenle, E.J.; Wollheim, C.B.; Gauthier, B.R. The diabetes-linked transcription factor PAX4 promotes β-cell proliferation and survival in rat and human islets. J. Cell Biol. 2004, 167, 1123–1135. [CrossRef]

159. Rezende, L.F.; Stoppiglia, L.F.; Souza, K.L.; Negro, A.; Langone, F.; Boschero, A.C. Ciliary neurotrophic factor promotes survival of neonatal rat islets via the BCL-2 anti-apoptotic pathway. J. Endocrinol. 2007, 195, 157–165. [CrossRef]

160. Hu He, K.H.; Lorenzo, P.I.; Brun, T.; Jimenez Moreno, C.M.; Aeberhard, D.; Vallejo Ortega, J.; Cornu, M.; Thorel, F.; Gjinovci, A.; Thorens, B.; et al. In vivo conditional Pax4 overexpression in mature islet β-cells prevents stress-induced hyperglycemia in mice. Diabetes 2011, 60, 1705–1715. [CrossRef]

161. Sujjitjoon, J.; Kooptiwut, S.; Chongjaroen, N.; Tangjittipokin, W.; Plengvidhya, N.; Yenchitsomanus, P.T. Aberrant mRNA splicing of paired box 4 (PAX4) IVS7-1G>A mutation causing maturity-onset diabetes of the young, type 9. Acta Diabetol. 2016, 53, 205–216. [CrossRef]

162. Lei, S.Q.; Wang, J.Y.; Li, R.M.; Chang, J.; Li, Z.; Ren, L.; Sang, Y.M. MODY10 caused by c.309-314del CCAGCT insGCGC mutation of the insulin gene: A case report. Am. J. Transl. Res. 2020, 12, 6599–6607.

163. Yan, J.; Jiang, F.; Zhang, R.; Xu, T.; Zhou, Z.; Ren, W.; Peng, D.; Liu, Y.; Hu, C.; Jia, W. Whole-exome sequencing identiﬁes a novel INS mutation causative of maturity-onset diabetes of the young 10. J. Mol. Cell Biol. 2017, 9, 376–383. [CrossRef] [PubMed]

164. Zhang, J.; Liu, Y.; Li, M.; Ge, X.; Wang, Y.; Huang, X.; Yang, D.; Zhan, R.; Chen, Y.; Lu, M.; et al. Identiﬁcation of Ala2Thr mutation in insulin gene from a Chinese MODY10 family. Mol. Cell. Biochem. 2020, 470, 77–86. [CrossRef] [PubMed]

165. Lin, L.; Quan, H.; Chen, K.; Chen, D.; Lin, D.; Fang, T. ABCC8-Related Maturity-Onset Diabetes of the Young (MODY12): A Report of a Chinese Family. Front. Endocrinol. (Lausanne) 2020, 11, 645. [CrossRef]

166. Laver, T.W.; Wakeling, M.N.; Knox, O.; Colclough, K.; Wright, C.F.; Ellard, S.; Hattersley, A.T.; Weedon, M.N.; Patel, K.A. Evaluation of evidence for pathogenicity demonstrates that BLK, KLF11, and PAX4 should not be included in diagnostic testing for MODY. Diabetes 2022, 71, 1128–1136. [CrossRef] [PubMed]